What Is Skyrizi? Uses, Dosage, and What You Need to Know in 2026

Skyrizi (pronounced sky-RIZZ-ee) is a prescription biologic medication manufactured by AbbVie. Its generic name is risankizumab-rzaa. Since its first FDA approval in 2019, Skyrizi has become one of the most prescribed biologics for treating immune-mediated inflammatory diseases. This guide covers what Skyrizi is, what it treats, how it's given, and what patients need to know in 2026.

What Conditions Does Skyrizi Treat?

Skyrizi is FDA-approved for four conditions in adults:

Moderate to severe plaque psoriasis (approved April 2019): For adults who are candidates for systemic therapy or phototherapy. Skyrizi can produce clear or almost-clear skin in a significant percentage of patients.

Active psoriatic arthritis (approved January 2022): For adults with the joint inflammation associated with psoriasis. Can be used alone or with non-biologic DMARDs.

Moderately to severely active Crohn's disease (approved June 2022): For adults. Skyrizi was the first IL-23-selective biologic approved for Crohn's disease.

Moderately to severely active ulcerative colitis (approved): For adults with inadequate response to conventional therapy or biologics.

What Drug Class Is Skyrizi?

Skyrizi is classified as an interleukin-23 (IL-23) antagonist—specifically a humanized IgG1 monoclonal antibody that selectively targets the p19 subunit of IL-23. It belongs to the broader category of biologic medications (drugs made from living cells). Skyrizi is not a controlled substance and has no DEA schedule.

How Is Skyrizi Given?

How Skyrizi is administered depends on which condition is being treated:

For plaque psoriasis and psoriatic arthritis: 150 mg given as a subcutaneous (under the skin) injection at weeks 0 and 4 (two loading doses), then 150 mg every 12 weeks (once every 3 months) for maintenance. This is only 4–5 injections per year during maintenance.

For Crohn's disease and ulcerative colitis (induction): 600 mg given as an intravenous (IV) infusion at weeks 0, 4, and 8—three doses administered in a healthcare setting.

For Crohn's disease and ulcerative colitis (maintenance): Starting 4 weeks after the last IV induction dose, 360 mg or 180 mg given as a subcutaneous injection every 8 weeks (approximately once every 2 months).

What Does Skyrizi Look Like and How Is It Stored?

Skyrizi comes in several forms:

150 mg/mL prefilled autoinjector pen (for psoriasis/PsA)

150 mg/mL prefilled syringe (for psoriasis/PsA)

600 mg/10 mL single-dose vial (for IBD induction, given by a healthcare provider)

180 mg/1.2 mL or 360 mg/2.4 mL prefilled cartridge with on-body injector (for IBD maintenance)

Skyrizi must be stored in the refrigerator at 36°F–46°F (2°C–8°C). Do not freeze, shake, or expose to direct light. Before injecting, allow it to reach room temperature (30–90 minutes for the pen; 15–30 minutes for the syringe) outside of the refrigerator without removing it from the carton. Never use Skyrizi that has been frozen or that contains large particles or discoloration.

Who Should Not Take Skyrizi?

Skyrizi is contraindicated (should not be used) in patients who have had a serious allergic reaction (including anaphylaxis) to risankizumab or any of its ingredients. Additionally, Skyrizi should not be started in patients with an active clinically important infection. Patients with a history of TB or recent exposure to TB require evaluation before starting Skyrizi.

Is Skyrizi Available as a Generic?

No. As of 2026, Skyrizi has no FDA-approved generic or biosimilar equivalent. It remains a branded medication exclusively manufactured by AbbVie. This means the medication costs are significant without insurance or manufacturer assistance programs.

See our guide on How to Save Money on Skyrizi in 2026 for a complete breakdown of all patient assistance and savings programs.

Once you have your prescription, medfinder can help you find which specialty pharmacies can fill it—saving you time and effort in navigating the specialty pharmacy system.